D&Amp;D Pharmatech Raises $51M In Series C Financing To Advance Potential Disease-Modifying Treatments For Neurodegenerative, Fibrotic, And Metabolic Diseases
D&Amp;D Pharmatech Raises $51M In Series C Financing To Advance Potential Disease-Modifying Treatments For Neurodegenerative, Fibrotic, And Metabolic Diseases
10/19/21, 11:00 AM
Money raised
$51 million
Industry
mobile
health care
Round Type
series c
D&D Pharmatech Inc., a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, and parent company of U.S.-based Neuraly Inc., Precision Molecular, Inc., Theraly Fibrosis Inc., P4Microbiome and Valted Seq, today announced that it has completed a $51 million Series C round of financing led by Praxis Capital Partners, a private equity firm that focuses on growth acquisitions and investments in Asia; other investors included DS Asset Management, Kudos Ventures and Korea Investment & Securities. The new round of financing builds upon the $137.1 million the company secured in Series B financing in August 2019. The company is planning an initial public offering in Korea in 2022.
Company Info
Additional Info
D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The company’s product pipeline focuses on a range of indications including neurodegenerative, fibrotic and metabolic diseases. D&D Pharmatech is the parent company of U.S.-based Neuraly Inc., Theraly Fibrosis Inc., Precision Molecular Inc., P4Microbiome and Valted Seq, Inc. For more information, please visit http://www.ddpharmatech.com/